Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO • First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS). • With a median...
EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The data demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma, with notable disease-free survival rates. Investigators concluded that the combination of efti, KEYTRUDA, and radiotherapy as neoadjuvant therapy shows promise for further trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Story so far
Earlier from Immutep
- IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
- IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition
- Upcoming Poster Presentations at CTOS and ESMO IO 2026
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Receives A$2.16 million French R&D Tax Incentive
Later from Immutep
- Immutep Expands US Patents for Efti Combination Therapies
- Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
- Immutep Investor Update
- Encouraging Disease-Free Survival in Phase II Sarcoma Trial
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep